Arexis AB Enters Into Collaboration With CMC Biopharmaceuticals

The drug development company Arexis AB has entered into a collaboration agreement with the Danish company CMC Biopharmaceuticals on the production of recombinant human BSSL for the upcoming cystic fibrosis and preterm infant clinical trials. The collaboration represents an important step in the preparations for the BSSL (bile salt-stimulated lipase) clinical trials in cystic fibrosis patients with fat malabsorption and preterm infants.

BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19323220&full=1)